Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16687945 | 0.91 | ALDH1A1 (0.48) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29355223 | 0.90 | HPGD (0.42) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL43173 | 0.90 | HPGD (0.42) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31005444 | 0.90 | HPGD (0.42) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29130297 | 0.88 | ALDH1A1 (0.48) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14273419 | 0.86 | HPGD (0.43) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31005443 | 0.86 | HPGD (0.43) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20983700 | 0.85 | ALDH1A1 (0.50) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL277974 | 0.85 | ALDH1A1 (0.56) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30498662 | 0.85 | ALDH1A1 (0.56) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849134-B | Methods of mediating cytokine expression with anti-CCR 4 antibodies | 达纳－法伯癌症研究所公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-104994885-B | Method and composition for radiohalogen protein labeling | 基因泰克公司 | 2017-09-29 | — | — | CN | disclosed |
| US-8846080-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2014-09-30 | — | — | US | disclosed |
| US-20140162906-A1 | Pesticide Biomarker | NAGY JON OWEN (US) | 2014-06-12 | — | — | US | disclosed |
| US-20110166043-A1 | BIOMARKER DETECTION-2 | ATERIS TECHNOLOGIES, LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110159081-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS S.A. | 2011-06-30 | — | — | US | disclosed |
| EP-2328613-A1 | VACCINE | GlaxoSmithKline Biologicals S.A. (BE) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010023216-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2010-03-04 | — | — | WO | disclosed |
| US-20100041077-A1 | PESTICIDE BIOMARKER | ATERIS TECHNOLOGIES, LLC | 2010-02-18 | — | — | US | disclosed |
| EP-1032427-A2 | CONJUGATES OF CYTOKINES AND DRUGS OR GENES FOR TREATING PROLIFERATING CELLS | Bioinnovation Limited (GB) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026660-A2 | CONJUGATES OF CYTOKINES AND DRUGS OR GENES FOR TREATING PROLIFERATING CELLS | BIOINNOVATION LIMITED (GB) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166043-A1 | BIOMARKER DETECTION-2 | CPB2, NAALAD2, PRSS2 | HPGD 714/4885ALDH1A1 1052/4885NPC1 4296/4885 |
| US-20110159081-A1 | VACCINE | LY96, CD47, CD74 | HPGD 1987/4885ALDH1A1 4568/4885NPC1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.